CONCLUSION
The study demonstrates that 40 mg dose of 6MP PFOS 10 mg/mL has the same
extent of absorption as the 50 mg tablet which can be precisely
administered in pediatrics. The study also demonstrates the role of
modelling and simulation to perform virtual bioequivalence and
paediatric studies.
What is already known about this subject:
- 50mg tablet formulation of 6 Mercaptopurine is extensively used in
acute lymphoblastic leukaemia (ALL) in both children and adults.
- Significant differences in 6 Mercaptopurine exposures and response
necessitate dosage adjustments.
- Suspensions are generally absorbed more readily than solid
formulations, as they do not require disintegration.
What this study adds:
- Demonstrates an equivalent dose of a new 6MP liquid formulation to
tablets.
- Emphasise the need to switch to formulations that enable precision
dosing.
- Highlights the role of modelling and simulation in dose optimisation.